Q3 FY2025 Earnings
Financial report interval: 2025.06.30 - 2025.09.30
Overview: Carisma Therapeutics(CARM) the Revenue is 45.25 M (+1237%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.05B1236.78%
0.00B100.00%
+0.05B1,336.78%
EBIT
TBA--
-0.01B61.96%
----
EPS
TBA--
-0.1261.29%
----
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf